Leukemia Home > Clolar and Pregnancy
Women who are going to receive Clolar (clofarabine) and are of childbearing age should use an effective form of birth control during treatment. When this drug was given to pregnant animals, it caused a number of problems, including miscarriages and birth defects. As a pregnancy Category D medicine, Clolar should only be given to a pregnant woman when the benefits outweigh the risks.
Clolar® (clofarabine) is a prescription medication approved for the treatment of acute lymphoblastic leukemia in children age 1 to 21 years old who have failed treatment with at least two previous treatment regimens. Clolar is considered a pregnancy Category D medication because it may harm an unborn child.
The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category D is a classification given to medicines that have been shown to present a risk to the fetus in studies of pregnant women but may still offer benefits that outweigh the risks the drug presents.
A pregnancy Category D medicine may still be given to a pregnant woman if her healthcare provider believes that the benefits to the woman outweigh the possible risks to her unborn child.
Clolar has not been adequately studied in pregnant women. In animal studies, the drug caused a variety of problems when given to pregnant rats and rabbits, including decreased fetal weight, miscarriages, and defects of the bones and soft tissues.
In general, this medication is not recommended for use in pregnant women. Males and females who can conceive children should use an effective form of birth control during Clolar treatment to avoid pregnancy. However, because acute lymphoblastic leukemia is potentially life-threatening, a healthcare provider may continue to recommend the drug, despite the risks, if a woman becomes pregnant during treatment.